DUBLIN, IRELAND – November 13, 2018 – ATXA Therapeutics Ltd CEO, Dr. Ivan Coulter will today attend the Biotech and Money Inv€$tival Showcase conference in London. The Biotech and Money Inv€$tival showcase organized by LSX and partnered with Jefferies, connects corporates to capital by showcasing innovative investable life science and healthcare investment and partnering opportunities.
November 14, 2018, Dr. Coulter will also be attending the Jefferies London Healthcare conference at the same venue.
About ATXA Therapeutics
Headquartered in Dublin, Ireland, ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded in May 2015, ATXA Therapeutics Limited is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. For more information, please visit www.atxatherapeutics.com.
Press Contact: email@example.com